<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 19:02:03 -0700</creation_date>
  <update_date>2013-05-27 11:06:12 -0600</update_date>
  <accession>HMDBP02058</accession>
  <secondary_accessions>
    <accession>7537</accession>
    <accession>HMDBP04946</accession>
  </secondary_accessions>
  <protein_type>Unknown</protein_type>
  <synonyms>
    <synonym>CA-II</synonym>
    <synonym>CAC</synonym>
    <synonym>Carbonate dehydratase II</synonym>
    <synonym>Carbonic anhydrase C</synonym>
    <synonym>Carbonic anhydrase II</synonym>
  </synonyms>
  <gene_name>CA2</gene_name>
  <general_function>Involved in carbonate dehydratase activity</general_function>
  <specific_function>Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion into the anterior chamber of the eye.
</specific_function>
  <pathways>
    <pathway>
      <name>Proximal tubule bicarbonate reclamation</name>
      <smpdb_id/>
      <kegg_map_id>map04964</kegg_map_id>
    </pathway>
    <pathway>
      <name>Collecting duct acid secretion</name>
      <smpdb_id/>
      <kegg_map_id>map04966</kegg_map_id>
    </pathway>
    <pathway>
      <name>Gastric acid secretion</name>
      <smpdb_id/>
      <kegg_map_id>map04971</kegg_map_id>
    </pathway>
    <pathway>
      <name>Pancreatic secretion</name>
      <smpdb_id/>
      <kegg_map_id>map04972</kegg_map_id>
    </pathway>
    <pathway>
      <name>Bile secretion</name>
      <smpdb_id/>
      <kegg_map_id>map04976</kegg_map_id>
    </pathway>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB05034</accession>
      <name>Topiramate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01928</accession>
      <name>Hydrochlorothiazide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01303</accession>
      <name>Zinc (II) ion</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01967</accession>
      <name>Carbon dioxide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB02111</accession>
      <name>Water</name>
    </metabolite>
    <metabolite>
      <accession>HMDB03538</accession>
      <name>Carbonic acid</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14377</accession>
      <name>Methyclothiazide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14456</accession>
      <name>Ethoxzolamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14580</accession>
      <name>Bendroflumethiazide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14702</accession>
      <name>Benzthiazide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14744</accession>
      <name>Cyclothiazide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB01933</accession>
      <name>Furosemide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14841</accession>
      <name>Methazolamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14912</accession>
      <name>Hydroflumethiazide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14957</accession>
      <name>Acetazolamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15007</accession>
      <name>Dorzolamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15018</accession>
      <name>Chlorothiazide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15045</accession>
      <name>Zonisamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15156</accession>
      <name>Trichlormethiazide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15165</accession>
      <name>Ethinamate</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15251</accession>
      <name>Diazoxide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15275</accession>
      <name>Dichlorphenamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15325</accession>
      <name>Brinzolamide</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15420</accession>
      <name>Quinethazone</name>
    </metabolite>
    <metabolite>
      <accession>HMDB00294</accession>
      <name>Urea</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>function</category>
      <description>binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>cation binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>metal ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>transition metal ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>zinc ion binding</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>catalytic activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>lyase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>carbon-oxygen lyase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>hydro-lyase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>function</category>
      <description>carbonate dehydratase activity</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cellular metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>one-carbon metabolic process</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>apical part of cell</description>
      <go_id>GO:0045177</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>axon</description>
      <go_id>GO:0030424</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>basolateral plasma membrane</description>
      <go_id>GO:0016323</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>cytosol</description>
      <go_id>GO:0005829</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>extracellular space</description>
      <go_id>GO:0005615</go_id>
    </go_class>
    <go_class>
      <category>Cellular component</category>
      <description>microvillus</description>
      <go_id>GO:0005902</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>carbonate dehydratase activity</description>
      <go_id>GO:0004089</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>metal ion binding</description>
      <go_id>GO:0046872</go_id>
    </go_class>
    <go_class>
      <category>Molecular function</category>
      <description>zinc ion binding</description>
      <go_id>GO:0008270</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>bicarbonate transport</description>
      <go_id>GO:0015701</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>carbon dioxide transport</description>
      <go_id>GO:0015670</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>kidney development</description>
      <go_id>GO:0001822</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>morphogenesis of an epithelium</description>
      <go_id>GO:0002009</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>odontogenesis of dentin-containing tooth</description>
      <go_id>GO:0042475</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>one-carbon metabolic process</description>
      <go_id>GO:0006730</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of bone resorption</description>
      <go_id>GO:0045780</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of cellular pH reduction</description>
      <go_id>GO:0032849</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>positive regulation of osteoclast differentiation</description>
      <go_id>GO:0045672</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to estrogen stimulus</description>
      <go_id>GO:0043627</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to pH</description>
      <go_id>GO:0009268</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to stress</description>
      <go_id>GO:0006950</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>response to zinc ion</description>
      <go_id>GO:0010043</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>secretion</description>
      <go_id>GO:0046903</go_id>
    </go_class>
    <go_class>
      <category>Biological process</category>
      <description>small molecule metabolic process</description>
      <go_id>GO:0044281</go_id>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Cytoplasm</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>8</chromosome_location>
    <locus>8q22</locus>
    <gene_sequence>&gt;783 bp
ATGTCCCATCACTGGGGGTACGGCAAACACAACGGACCTGAGCACTGGCATAAGGACTTC
CCCATTGCCAAGGGAGAGCGCCAGTCCCCTGTTGACATCGACACTCATACAGCCAAGTAT
GACCCTTCCCTGAAGCCCCTGTCTGTTTCCTATGATCAAGCAACTTCCCTGAGGATCCTC
AACAATGGTCATGCTTTCAACGTGGAGTTTGATGACTCTCAGGACAAAGCAGTGCTCAAG
GGAGGACCCCTGGATGGCACTTACAGATTGATTCAGTTTCACTTTCACTGGGGTTCACTT
GATGGACAAGGTTCAGAGCATACTGTGGATAAAAAGAAATATGCTGCAGAACTTCACTTG
GTTCACTGGAACACCAAATATGGGGATTTTGGGAAAGCTGTGCAGCAACCTGATGGACTG
GCCGTTCTAGGTATTTTTTTGAAGGTTGGCAGCGCTAAACCGGGCCTTCAGAAAGTTGTT
GATGTGCTGGATTCCATTAAAACAAAGGGCAAGAGTGCTGACTTCACTAACTTCGATCCT
CGTGGCCTCCTTCCTGAATCCCTGGATTACTGGACCTACCCAGGCTCACTGACCACCCCT
CCTCTTCTGGAATGTGTGACCTGGATTGTGCTCAAGGAACCCATCAGCGTCAGCAGCGAG
CAGGTGTTGAAATTCCGTAAACTTAACTTCAATGGGGAGGGTGAACCCGAAGAACTGATG
GTGGACAACTGGCGCCCAGCTCAGCCACTGAAGAACAGGCAAATCAAAGCTTCCTTCAAA
TAA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>260</residue_number>
    <molecular_weight>29245.895</molecular_weight>
    <theoretical_pi>7.405</theoretical_pi>
    <pfams>
      <pfam>
        <name>Carb_anhydrase</name>
        <pfam_id>PF00194</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
    </transmembrane_regions>
    <signal_regions>
    </signal_regions>
    <protein_sequence>&gt;Carbonic anhydrase 2
MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRIL
NNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHL
VHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDP
RGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELM
VDNWRPAQPLKNRQIKASFK</protein_sequence>
  </protein_properties>
  <genbank_protein_id>29587</genbank_protein_id>
  <uniprot_id>P00918</uniprot_id>
  <uniprot_name>CAH2_HUMAN</uniprot_name>
  <pdb_ids>
    <pdb_id>12CA</pdb_id>
    <pdb_id>1A42</pdb_id>
    <pdb_id>1AM6</pdb_id>
    <pdb_id>1AVN</pdb_id>
    <pdb_id>1BCD</pdb_id>
    <pdb_id>1BIC</pdb_id>
    <pdb_id>1BN1</pdb_id>
    <pdb_id>1BN3</pdb_id>
    <pdb_id>1BN4</pdb_id>
    <pdb_id>1BNM</pdb_id>
    <pdb_id>1BNN</pdb_id>
    <pdb_id>1BNQ</pdb_id>
    <pdb_id>1BNT</pdb_id>
    <pdb_id>1BNU</pdb_id>
    <pdb_id>1BNV</pdb_id>
    <pdb_id>1BNW</pdb_id>
    <pdb_id>1BV3</pdb_id>
    <pdb_id>1CA2</pdb_id>
    <pdb_id>1CA3</pdb_id>
    <pdb_id>1CAH</pdb_id>
    <pdb_id>1CAI</pdb_id>
    <pdb_id>1CAJ</pdb_id>
    <pdb_id>1CAK</pdb_id>
    <pdb_id>1CAL</pdb_id>
    <pdb_id>1CAM</pdb_id>
    <pdb_id>1CAN</pdb_id>
    <pdb_id>1CAO</pdb_id>
    <pdb_id>1CAY</pdb_id>
    <pdb_id>1CAZ</pdb_id>
    <pdb_id>1CCS</pdb_id>
    <pdb_id>1CCT</pdb_id>
    <pdb_id>1CCU</pdb_id>
    <pdb_id>1CIL</pdb_id>
    <pdb_id>1CIM</pdb_id>
    <pdb_id>1CIN</pdb_id>
    <pdb_id>1CNB</pdb_id>
    <pdb_id>1CNC</pdb_id>
    <pdb_id>1CNG</pdb_id>
    <pdb_id>1CNH</pdb_id>
    <pdb_id>1CNI</pdb_id>
    <pdb_id>1CNJ</pdb_id>
    <pdb_id>1CNK</pdb_id>
    <pdb_id>1CNW</pdb_id>
    <pdb_id>1CNX</pdb_id>
    <pdb_id>1CNY</pdb_id>
    <pdb_id>1CRA</pdb_id>
    <pdb_id>1CVA</pdb_id>
    <pdb_id>1CVB</pdb_id>
    <pdb_id>1CVC</pdb_id>
    <pdb_id>1CVD</pdb_id>
    <pdb_id>1CVE</pdb_id>
    <pdb_id>1CVF</pdb_id>
    <pdb_id>1CVH</pdb_id>
    <pdb_id>1DCA</pdb_id>
    <pdb_id>1DCB</pdb_id>
    <pdb_id>1EOU</pdb_id>
    <pdb_id>1F2W</pdb_id>
    <pdb_id>1FQL</pdb_id>
    <pdb_id>1FQM</pdb_id>
    <pdb_id>1FQN</pdb_id>
    <pdb_id>1FQR</pdb_id>
    <pdb_id>1FR4</pdb_id>
    <pdb_id>1FR7</pdb_id>
    <pdb_id>1FSN</pdb_id>
    <pdb_id>1FSQ</pdb_id>
    <pdb_id>1FSR</pdb_id>
    <pdb_id>1G0E</pdb_id>
    <pdb_id>1G0F</pdb_id>
    <pdb_id>1G1D</pdb_id>
    <pdb_id>1G3Z</pdb_id>
    <pdb_id>1G45</pdb_id>
    <pdb_id>1G46</pdb_id>
    <pdb_id>1G48</pdb_id>
    <pdb_id>1G4J</pdb_id>
    <pdb_id>1G4O</pdb_id>
    <pdb_id>1G52</pdb_id>
    <pdb_id>1G53</pdb_id>
    <pdb_id>1G54</pdb_id>
    <pdb_id>1H4N</pdb_id>
    <pdb_id>1H9N</pdb_id>
    <pdb_id>1H9Q</pdb_id>
    <pdb_id>1HCA</pdb_id>
    <pdb_id>1HEA</pdb_id>
    <pdb_id>1HEB</pdb_id>
    <pdb_id>1HEC</pdb_id>
    <pdb_id>1HED</pdb_id>
    <pdb_id>1HVA</pdb_id>
    <pdb_id>1I8Z</pdb_id>
    <pdb_id>1I90</pdb_id>
    <pdb_id>1I91</pdb_id>
    <pdb_id>1I9L</pdb_id>
    <pdb_id>1I9M</pdb_id>
    <pdb_id>1I9N</pdb_id>
    <pdb_id>1I9O</pdb_id>
    <pdb_id>1I9P</pdb_id>
    <pdb_id>1I9Q</pdb_id>
    <pdb_id>1IF4</pdb_id>
    <pdb_id>1IF5</pdb_id>
    <pdb_id>1IF6</pdb_id>
    <pdb_id>1IF7</pdb_id>
    <pdb_id>1IF8</pdb_id>
    <pdb_id>1IF9</pdb_id>
    <pdb_id>1KWQ</pdb_id>
    <pdb_id>1KWR</pdb_id>
    <pdb_id>1LG5</pdb_id>
    <pdb_id>1LG6</pdb_id>
    <pdb_id>1LGD</pdb_id>
    <pdb_id>1LUG</pdb_id>
    <pdb_id>1LZV</pdb_id>
    <pdb_id>1MOO</pdb_id>
    <pdb_id>1MUA</pdb_id>
    <pdb_id>1OKL</pdb_id>
    <pdb_id>1OKM</pdb_id>
    <pdb_id>1OKN</pdb_id>
    <pdb_id>1OQ5</pdb_id>
    <pdb_id>1RAY</pdb_id>
    <pdb_id>1RAZ</pdb_id>
    <pdb_id>1RZA</pdb_id>
    <pdb_id>1RZB</pdb_id>
    <pdb_id>1RZC</pdb_id>
    <pdb_id>1RZD</pdb_id>
    <pdb_id>1RZE</pdb_id>
    <pdb_id>1T9N</pdb_id>
    <pdb_id>1TB0</pdb_id>
    <pdb_id>1TBT</pdb_id>
    <pdb_id>1TE3</pdb_id>
    <pdb_id>1TEQ</pdb_id>
    <pdb_id>1TEU</pdb_id>
    <pdb_id>1TG3</pdb_id>
    <pdb_id>1TG9</pdb_id>
    <pdb_id>1TH9</pdb_id>
    <pdb_id>1THK</pdb_id>
    <pdb_id>1TTM</pdb_id>
    <pdb_id>1UGA</pdb_id>
    <pdb_id>1UGB</pdb_id>
    <pdb_id>1UGC</pdb_id>
    <pdb_id>1UGD</pdb_id>
    <pdb_id>1UGE</pdb_id>
    <pdb_id>1UGF</pdb_id>
    <pdb_id>1UGG</pdb_id>
    <pdb_id>1XEG</pdb_id>
    <pdb_id>1XEV</pdb_id>
    <pdb_id>1XPZ</pdb_id>
    <pdb_id>1XQ0</pdb_id>
    <pdb_id>1YDA</pdb_id>
    <pdb_id>1YDB</pdb_id>
    <pdb_id>1YDC</pdb_id>
    <pdb_id>1YDD</pdb_id>
    <pdb_id>1YO0</pdb_id>
    <pdb_id>1YO1</pdb_id>
    <pdb_id>1YO2</pdb_id>
    <pdb_id>1Z9Y</pdb_id>
    <pdb_id>1ZE8</pdb_id>
    <pdb_id>1ZFK</pdb_id>
    <pdb_id>1ZFQ</pdb_id>
    <pdb_id>1ZGE</pdb_id>
    <pdb_id>1ZGF</pdb_id>
    <pdb_id>1ZH9</pdb_id>
    <pdb_id>1ZSA</pdb_id>
    <pdb_id>1ZSB</pdb_id>
    <pdb_id>1ZSC</pdb_id>
    <pdb_id>2ABE</pdb_id>
    <pdb_id>2AW1</pdb_id>
    <pdb_id>2AX2</pdb_id>
    <pdb_id>2CA2</pdb_id>
    <pdb_id>2CBA</pdb_id>
    <pdb_id>2CBB</pdb_id>
    <pdb_id>2CBC</pdb_id>
    <pdb_id>2CBD</pdb_id>
    <pdb_id>2CBE</pdb_id>
    <pdb_id>2EU2</pdb_id>
    <pdb_id>2EU3</pdb_id>
    <pdb_id>2EZ7</pdb_id>
    <pdb_id>2F14</pdb_id>
    <pdb_id>2FMG</pdb_id>
    <pdb_id>2FMZ</pdb_id>
    <pdb_id>2FNK</pdb_id>
    <pdb_id>2FNM</pdb_id>
    <pdb_id>2FNN</pdb_id>
    <pdb_id>2FOQ</pdb_id>
    <pdb_id>2FOS</pdb_id>
    <pdb_id>2FOU</pdb_id>
    <pdb_id>2FOV</pdb_id>
    <pdb_id>2GD8</pdb_id>
    <pdb_id>2GEH</pdb_id>
    <pdb_id>2H15</pdb_id>
    <pdb_id>2H4N</pdb_id>
    <pdb_id>2HD6</pdb_id>
    <pdb_id>2HKK</pdb_id>
    <pdb_id>2HL4</pdb_id>
    <pdb_id>2HNC</pdb_id>
    <pdb_id>2HOC</pdb_id>
    <pdb_id>2ILI</pdb_id>
    <pdb_id>2NNG</pdb_id>
    <pdb_id>2NNO</pdb_id>
    <pdb_id>2NNS</pdb_id>
    <pdb_id>2NNV</pdb_id>
    <pdb_id>2NWO</pdb_id>
    <pdb_id>2NWP</pdb_id>
    <pdb_id>2NWY</pdb_id>
    <pdb_id>2NWZ</pdb_id>
    <pdb_id>2NXR</pdb_id>
    <pdb_id>2NXS</pdb_id>
    <pdb_id>2NXT</pdb_id>
    <pdb_id>2O4Z</pdb_id>
    <pdb_id>2OSF</pdb_id>
    <pdb_id>2OSM</pdb_id>
    <pdb_id>2POU</pdb_id>
    <pdb_id>2POV</pdb_id>
    <pdb_id>2POW</pdb_id>
    <pdb_id>2Q1B</pdb_id>
    <pdb_id>2Q1Q</pdb_id>
    <pdb_id>2Q38</pdb_id>
    <pdb_id>2QO8</pdb_id>
    <pdb_id>2QOA</pdb_id>
    <pdb_id>2QP6</pdb_id>
    <pdb_id>2VVA</pdb_id>
    <pdb_id>2VVB</pdb_id>
    <pdb_id>2WD2</pdb_id>
    <pdb_id>2WD3</pdb_id>
    <pdb_id>2WEG</pdb_id>
    <pdb_id>2WEH</pdb_id>
    <pdb_id>2WEJ</pdb_id>
    <pdb_id>2WEO</pdb_id>
    <pdb_id>2X7S</pdb_id>
    <pdb_id>2X7T</pdb_id>
    <pdb_id>2X7U</pdb_id>
    <pdb_id>3B4F</pdb_id>
    <pdb_id>3BET</pdb_id>
    <pdb_id>3BL0</pdb_id>
    <pdb_id>3BL1</pdb_id>
    <pdb_id>3C7P</pdb_id>
    <pdb_id>3CA2</pdb_id>
    <pdb_id>3CAJ</pdb_id>
    <pdb_id>3CYU</pdb_id>
    <pdb_id>3D8W</pdb_id>
    <pdb_id>3D92</pdb_id>
    <pdb_id>3D93</pdb_id>
    <pdb_id>3D9Z</pdb_id>
    <pdb_id>3DAZ</pdb_id>
    <pdb_id>3DBU</pdb_id>
    <pdb_id>3DC3</pdb_id>
    <pdb_id>3DC9</pdb_id>
    <pdb_id>3DCC</pdb_id>
    <pdb_id>3DCS</pdb_id>
    <pdb_id>3DCW</pdb_id>
    <pdb_id>3DD0</pdb_id>
    <pdb_id>3DD8</pdb_id>
    <pdb_id>3DV7</pdb_id>
    <pdb_id>3DVB</pdb_id>
    <pdb_id>3DVC</pdb_id>
    <pdb_id>3DVD</pdb_id>
    <pdb_id>3EFT</pdb_id>
    <pdb_id>3F4X</pdb_id>
    <pdb_id>3F8E</pdb_id>
    <pdb_id>3FFP</pdb_id>
    <pdb_id>3GZ0</pdb_id>
    <pdb_id>3HFP</pdb_id>
    <pdb_id>3HKN</pdb_id>
    <pdb_id>3HKQ</pdb_id>
    <pdb_id>3HKT</pdb_id>
    <pdb_id>3HKU</pdb_id>
    <pdb_id>3HLJ</pdb_id>
    <pdb_id>3HS4</pdb_id>
    <pdb_id>3IBI</pdb_id>
    <pdb_id>3IBL</pdb_id>
    <pdb_id>3IBN</pdb_id>
    <pdb_id>3IBU</pdb_id>
    <pdb_id>3IEO</pdb_id>
    <pdb_id>3IGP</pdb_id>
    <pdb_id>3K2F</pdb_id>
    <pdb_id>3K34</pdb_id>
    <pdb_id>3K7K</pdb_id>
    <pdb_id>3KIG</pdb_id>
    <pdb_id>3KKX</pdb_id>
    <pdb_id>3KNE</pdb_id>
    <pdb_id>3KOI</pdb_id>
    <pdb_id>3KOK</pdb_id>
    <pdb_id>3KON</pdb_id>
    <pdb_id>3KS3</pdb_id>
    <pdb_id>3KWA</pdb_id>
    <pdb_id>3L14</pdb_id>
    <pdb_id>3M04</pdb_id>
    <pdb_id>3M14</pdb_id>
    <pdb_id>3M1J</pdb_id>
    <pdb_id>3M1K</pdb_id>
    <pdb_id>3M1Q</pdb_id>
    <pdb_id>3M1W</pdb_id>
    <pdb_id>3M2N</pdb_id>
    <pdb_id>3M2X</pdb_id>
    <pdb_id>3M2Y</pdb_id>
    <pdb_id>3M2Z</pdb_id>
    <pdb_id>3M3X</pdb_id>
    <pdb_id>3M40</pdb_id>
    <pdb_id>3M5E</pdb_id>
    <pdb_id>3M5S</pdb_id>
    <pdb_id>3M5T</pdb_id>
    <pdb_id>3M67</pdb_id>
    <pdb_id>3M96</pdb_id>
    <pdb_id>3M98</pdb_id>
    <pdb_id>3MHC</pdb_id>
    <pdb_id>3MHI</pdb_id>
    <pdb_id>3MHL</pdb_id>
    <pdb_id>3MHM</pdb_id>
    <pdb_id>3MHO</pdb_id>
    <pdb_id>3ML2</pdb_id>
    <pdb_id>3MMF</pdb_id>
    <pdb_id>3MNA</pdb_id>
    <pdb_id>3MNH</pdb_id>
    <pdb_id>3MNI</pdb_id>
    <pdb_id>3MNJ</pdb_id>
    <pdb_id>3MNK</pdb_id>
    <pdb_id>3MNU</pdb_id>
    <pdb_id>3MWO</pdb_id>
    <pdb_id>3MYQ</pdb_id>
    <pdb_id>3MZC</pdb_id>
    <pdb_id>3N0N</pdb_id>
    <pdb_id>3N2P</pdb_id>
    <pdb_id>3N3J</pdb_id>
    <pdb_id>3N4B</pdb_id>
    <pdb_id>3NB5</pdb_id>
    <pdb_id>3NI5</pdb_id>
    <pdb_id>3NJ9</pdb_id>
    <pdb_id>3OIK</pdb_id>
    <pdb_id>3OIL</pdb_id>
    <pdb_id>3OIM</pdb_id>
    <pdb_id>3OKU</pdb_id>
    <pdb_id>3OKV</pdb_id>
    <pdb_id>3OY0</pdb_id>
    <pdb_id>3OYQ</pdb_id>
    <pdb_id>3OYS</pdb_id>
    <pdb_id>3P25</pdb_id>
    <pdb_id>3P29</pdb_id>
    <pdb_id>3P3H</pdb_id>
    <pdb_id>3P3J</pdb_id>
    <pdb_id>3P44</pdb_id>
    <pdb_id>3P4V</pdb_id>
    <pdb_id>3P55</pdb_id>
    <pdb_id>3P58</pdb_id>
    <pdb_id>3P5A</pdb_id>
    <pdb_id>3P5L</pdb_id>
    <pdb_id>3PJJ</pdb_id>
    <pdb_id>3PO6</pdb_id>
    <pdb_id>3PYK</pdb_id>
    <pdb_id>3QYK</pdb_id>
    <pdb_id>3R16</pdb_id>
    <pdb_id>3R17</pdb_id>
    <pdb_id>3RG3</pdb_id>
    <pdb_id>3RG4</pdb_id>
    <pdb_id>3RGE</pdb_id>
    <pdb_id>3RJ7</pdb_id>
    <pdb_id>3RLD</pdb_id>
    <pdb_id>3RYJ</pdb_id>
    <pdb_id>3RYV</pdb_id>
    <pdb_id>3RYX</pdb_id>
    <pdb_id>3RYY</pdb_id>
    <pdb_id>3RYZ</pdb_id>
    <pdb_id>3RZ0</pdb_id>
    <pdb_id>3RZ1</pdb_id>
    <pdb_id>3RZ5</pdb_id>
    <pdb_id>3RZ7</pdb_id>
    <pdb_id>3RZ8</pdb_id>
    <pdb_id>3S71</pdb_id>
    <pdb_id>3S72</pdb_id>
    <pdb_id>3S73</pdb_id>
    <pdb_id>3S74</pdb_id>
    <pdb_id>3S75</pdb_id>
    <pdb_id>3S76</pdb_id>
    <pdb_id>3S77</pdb_id>
    <pdb_id>3S78</pdb_id>
    <pdb_id>3S8X</pdb_id>
    <pdb_id>3S9T</pdb_id>
    <pdb_id>3SAP</pdb_id>
    <pdb_id>3SAX</pdb_id>
    <pdb_id>3SBH</pdb_id>
    <pdb_id>3SBI</pdb_id>
    <pdb_id>3T5U</pdb_id>
    <pdb_id>3T5Z</pdb_id>
    <pdb_id>3T82</pdb_id>
    <pdb_id>3T83</pdb_id>
    <pdb_id>3T84</pdb_id>
    <pdb_id>3T85</pdb_id>
    <pdb_id>3TMJ</pdb_id>
    <pdb_id>3TVN</pdb_id>
    <pdb_id>3TVO</pdb_id>
    <pdb_id>3U3A</pdb_id>
    <pdb_id>3U45</pdb_id>
    <pdb_id>3U47</pdb_id>
    <pdb_id>3V2J</pdb_id>
    <pdb_id>3V2M</pdb_id>
    <pdb_id>3V3F</pdb_id>
    <pdb_id>3V3G</pdb_id>
    <pdb_id>3V3H</pdb_id>
    <pdb_id>3V3I</pdb_id>
    <pdb_id>3V3J</pdb_id>
    <pdb_id>3V5G</pdb_id>
    <pdb_id>3V7X</pdb_id>
    <pdb_id>3VBD</pdb_id>
    <pdb_id>4CA2</pdb_id>
    <pdb_id>4CAC</pdb_id>
    <pdb_id>4E3D</pdb_id>
    <pdb_id>4E3F</pdb_id>
    <pdb_id>4E3G</pdb_id>
    <pdb_id>4E3H</pdb_id>
    <pdb_id>4E49</pdb_id>
    <pdb_id>4E4A</pdb_id>
    <pdb_id>4FIK</pdb_id>
    <pdb_id>4FL7</pdb_id>
    <pdb_id>4G0C</pdb_id>
    <pdb_id>4IDR</pdb_id>
    <pdb_id>5CA2</pdb_id>
    <pdb_id>5CAC</pdb_id>
    <pdb_id>6CA2</pdb_id>
    <pdb_id>7CA2</pdb_id>
    <pdb_id>8CA2</pdb_id>
    <pdb_id>9CA2</pdb_id>
  </pdb_ids>
  <genbank_gene_id>Y00339</genbank_gene_id>
  <genecard_id>CA2</genecard_id>
  <geneatlas_id>CA2</geneatlas_id>
  <hgnc_id>HGNC:1373</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Montgomery JC, Venta PJ, Tashian RE, Hewett-Emmett D: Nucleotide sequence of human liver carbonic anhydrase II cDNA.  Nucleic Acids Res. 1987 Jun 11;15(11):4687.</reference_text>
      <pubmed_id>3108857</pubmed_id>
    </reference>
    <reference>
      <reference_text>Murakami H, Marelich GP, Grubb JH, Kyle JW, Sly WS: Cloning, expression, and sequence homologies of cDNA for human carbonic anhydrase II. Genomics. 1987 Oct;1(2):159-66.</reference_text>
      <pubmed_id>3121496</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, Irie R, Wakamatsu A, Hayashi K, Sato H, Nagai K, Kimura K, Makita H, Sekine M, Obayashi M, Nishi T, Shibahara T, Tanaka T, Ishii S, Yamamoto J, Saito K, Kawai Y, Isono Y, Nakamura Y, Nagahari K, Murakami K, Yasuda T, Iwayanagi T, Wagatsuma M, Shiratori A, Sudo H, Hosoiri T, Kaku Y, Kodaira H, Kondo H, Sugawara M, Takahashi M, Kanda K, Yokoi T, Furuya T, Kikkawa E, Omura Y, Abe K, Kamihara K, Katsuta N, Sato K, Tanikawa M, Yamazaki M, Ninomiya K, Ishibashi T, Yamashita H, Murakawa K, Fujimori K, Tanai H, Kimata M, Watanabe M, Hiraoka S, Chiba Y, Ishida S, Ono Y, Takiguchi S, Watanabe S, Yosida M, Hotuta T, Kusano J, Kanehori K, Takahashi-Fujii A, Hara H, Tanase TO, Nomura Y, Togiya S, Komai F, Hara R, Takeuchi K, Arita M, Imose N, Musashino K, Yuuki H, Oshima A, Sasaki N, Aotsuka S, Yoshikawa Y, Matsunawa H, Ichihara T, Shiohata N, Sano S, Moriya S, Momiyama H, Satoh N, Takami S, Terashima Y, Suzuki O, Nakagawa S, Senoh A, Mizoguchi H, Goto Y, Shimizu F, Wakebe H, Hishigaki H, Watanabe T, Sugiyama A, Takemoto M, Kawakami B, Yamazaki M, Watanabe K, Kumagai A, Itakura S, Fukuzumi Y, Fujimori Y, Komiyama M, Tashiro H, Tanigami A, Fujiwara T, Ono T, Yamada K, Fujii Y, Ozaki K, Hirao M, Ohmori Y, Kawabata A, Hikiji T, Kobatake N, Inagaki H, Ikema Y, Okamoto S, Okitani R, Kawakami T, Noguchi S, Itoh T, Shigeta K, Senba T, Matsumura K, Nakajima Y, Mizuno T, Morinaga M, Sasaki M, Togashi T, Oyama M, Hata H, Watanabe M, Komatsu T, Mizushima-Sugano J, Satoh T, Shirai Y, Takahashi Y, Nakagawa K, Okumura K, Nagase T, Nomura N, Kikuchi H, Masuho Y, Yamashita R, Nakai K, Yada T, Nakamura Y, Ohara O, Isogai T, Sugano S: Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet. 2004 Jan;36(1):40-5. Epub 2003 Dec 21.</reference_text>
      <pubmed_id>14702039</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Lin KT, Deutsch HF: Human carbonic anhydrases. XII. The complete primary structure of the C isozyme. J Biol Chem. 1974 Apr 25;249(8):2329-37.</reference_text>
      <pubmed_id>4207120</pubmed_id>
    </reference>
    <reference>
      <reference_text>Henderson LE, Henriksson D, Nyman PO: Primary structure of human carbonic anhydrase C.  J Biol Chem. 1976 Sep 25;251(18):5457-63.</reference_text>
      <pubmed_id>823150</pubmed_id>
    </reference>
    <reference>
      <reference_text>Venta PJ, Montgomery JC, Hewett-Emmett D, Tashian RE: Comparison of the 5' regions of human and mouse carbonic anhydrase II genes and identification of possible regulatory elements. Biochim Biophys Acta. 1985 Dec 18;826(4):195-201.</reference_text>
      <pubmed_id>3000449</pubmed_id>
    </reference>
    <reference>
      <reference_text>Alvarez BV, Loiselle FB, Supuran CT, Schwartz GJ, Casey JR: Direct extracellular interaction between carbonic anhydrase IV and the human NBC1 sodium/bicarbonate co-transporter. Biochemistry. 2003 Oct 28;42(42):12321-9.</reference_text>
      <pubmed_id>14567693</pubmed_id>
    </reference>
    <reference>
      <reference_text>Loiselle FB, Morgan PE, Alvarez BV, Casey JR: Regulation of the human NBC3 Na+/HCO3- cotransporter by carbonic anhydrase II and PKA. Am J Physiol Cell Physiol. 2004 Jun;286(6):C1423-33. Epub 2004 Jan 21.</reference_text>
      <pubmed_id>14736710</pubmed_id>
    </reference>
    <reference>
      <reference_text>Pushkin A, Abuladze N, Gross E, Newman D, Tatishchev S, Lee I, Fedotoff O, Bondar G, Azimov R, Ngyuen M, Kurtz I: Molecular mechanism of kNBC1-carbonic anhydrase II interaction in proximal tubule cells. J Physiol. 2004 Aug 15;559(Pt 1):55-65. Epub 2004 Jun 24.</reference_text>
      <pubmed_id>15218065</pubmed_id>
    </reference>
    <reference>
      <reference_text>Temperini C, Innocenti A, Guerri A, Scozzafava A, Rusconi S, Supuran CT: Phosph(on)ate as a zinc-binding group in metalloenzyme inhibitors: X-ray crystal structure of the antiviral drug foscarnet complexed to human carbonic anhydrase I. Bioorg Med Chem Lett. 2007 Apr 15;17(8):2210-5. Epub 2007 Feb 8.</reference_text>
      <pubmed_id>17314045</pubmed_id>
    </reference>
    <reference>
      <reference_text>Di Fiore A, Monti SM, Hilvo M, Parkkila S, Romano V, Scaloni A, Pedone C, Scozzafava A, Supuran CT, De Simone G: Crystal structure of human carbonic anhydrase XIII and its complex with the inhibitor acetazolamide. Proteins. 2009 Jan;74(1):164-75.</reference_text>
      <pubmed_id>18618712</pubmed_id>
    </reference>
    <reference>
      <reference_text>Liljas A, Kannan KK, Bergsten PC, Waara I, Fridborg K, Strandberg B, Carlbom U, Jarup L, Lovgren S, Petef M: Crystal structure of human carbonic anhydrase C.  Nat New Biol. 1972 Feb 2;235(57):131-7.</reference_text>
      <pubmed_id>4621826</pubmed_id>
    </reference>
    <reference>
      <reference_text>Eriksson AE, Jones TA, Liljas A: Refined structure of human carbonic anhydrase II at 2.0 A resolution.  Proteins. 1988;4(4):274-82.</reference_text>
      <pubmed_id>3151019</pubmed_id>
    </reference>
    <reference>
      <reference_text>Eriksson AE, Kylsten PM, Jones TA, Liljas A: Crystallographic studies of inhibitor binding sites in human carbonic anhydrase II: a pentacoordinated binding of the SCN- ion to the zinc at high pH. Proteins. 1988;4(4):283-93.</reference_text>
      <pubmed_id>3151020</pubmed_id>
    </reference>
    <reference>
      <reference_text>Krebs JF, Fierke CA, Alexander RS, Christianson DW: Conformational mobility of His-64 in the Thr-200----Ser mutant of human carbonic anhydrase II. Biochemistry. 1991 Sep 24;30(38):9153-60.</reference_text>
      <pubmed_id>1909891</pubmed_id>
    </reference>
    <reference>
      <reference_text>Alexander RS, Nair SK, Christianson DW: Engineering the hydrophobic pocket of carbonic anhydrase II.  Biochemistry. 1991 Nov 19;30(46):11064-72.</reference_text>
      <pubmed_id>1932029</pubmed_id>
    </reference>
    <reference>
      <reference_text>Nair SK, Calderone TL, Christianson DW, Fierke CA: Altering the mouth of a hydrophobic pocket. Structure and kinetics of human carbonic anhydrase II mutants at residue Val-121. J Biol Chem. 1991 Sep 15;266(26):17320-5.</reference_text>
      <pubmed_id>1910042</pubmed_id>
    </reference>
    <reference>
      <reference_text>Mangani S, Hakansson K: Crystallographic studies of the binding of protonated and unprotonated inhibitors to carbonic anhydrase using hydrogen sulphide and nitrate anions. Eur J Biochem. 1992 Dec 15;210(3):867-71.</reference_text>
      <pubmed_id>1336460</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hakansson K, Carlsson M, Svensson LA, Liljas A: Structure of native and apo carbonic anhydrase II and structure of some of its anion-ligand complexes. J Mol Biol. 1992 Oct 20;227(4):1192-204.</reference_text>
      <pubmed_id>1433293</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hakansson K, Wehnert A: Structure of cobalt carbonic anhydrase complexed with bicarbonate.  J Mol Biol. 1992 Dec 20;228(4):1212-8.</reference_text>
      <pubmed_id>1474587</pubmed_id>
    </reference>
    <reference>
      <reference_text>Alexander RS, Kiefer LL, Fierke CA, Christianson DW: Engineering the zinc binding site of human carbonic anhydrase II: structure of the His-94--&amp;gt;Cys apoenzyme in a new crystalline form. Biochemistry. 1993 Feb 16;32(6):1510-8.</reference_text>
      <pubmed_id>8431430</pubmed_id>
    </reference>
    <reference>
      <reference_text>Nair SK, Christianson DW: Structural consequences of hydrophilic amino acid substitutions in the hydrophobic pocket of human carbonic anhydrase II. Biochemistry. 1993 May 4;32(17):4506-14.</reference_text>
      <pubmed_id>8485129</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ippolito JA, Christianson DW: Structure of an engineered His3Cys zinc binding site in human carbonic anhydrase II. Biochemistry. 1993 Sep 28;32(38):9901-5.</reference_text>
      <pubmed_id>8399159</pubmed_id>
    </reference>
    <reference>
      <reference_text>Tweedy NB, Nair SK, Paterno SA, Fierke CA, Christianson DW: Structure and energetics of a non-proline cis-peptidyl linkage in a proline-202--&amp;gt;alanine carbonic anhydrase II variant. Biochemistry. 1993 Oct 19;32(41):10944-9.</reference_text>
      <pubmed_id>8218160</pubmed_id>
    </reference>
    <reference>
      <reference_text>Jonsson BM, Hakansson K, Liljas A: The structure of human carbonic anhydrase II in complex with bromide and azide. FEBS Lett. 1993 May 10;322(2):186-90.</reference_text>
      <pubmed_id>8482389</pubmed_id>
    </reference>
    <reference>
      <reference_text>Krebs JF, Ippolito JA, Christianson DW, Fierke CA: Structural and functional importance of a conserved hydrogen bond network in human carbonic anhydrase II. J Biol Chem. 1993 Dec 25;268(36):27458-66.</reference_text>
      <pubmed_id>8262987</pubmed_id>
    </reference>
    <reference>
      <reference_text>Mangani S, Liljas A: Crystal structure of the complex between human carbonic anhydrase II and the aromatic inhibitor 1,2,4-triazole. J Mol Biol. 1993 Jul 5;232(1):9-14.</reference_text>
      <pubmed_id>8331673</pubmed_id>
    </reference>
    <reference>
      <reference_text>Xue Y, Vidgren J, Svensson LA, Liljas A, Jonsson BH, Lindskog S: Crystallographic analysis of Thr-200--&amp;gt;His human carbonic anhydrase II and its complex with the substrate, HCO3-. Proteins. 1993 Jan;15(1):80-7.</reference_text>
      <pubmed_id>8451242</pubmed_id>
    </reference>
    <reference>
      <reference_text>Xue Y, Liljas A, Jonsson BH, Lindskog S: Structural analysis of the zinc hydroxide-Thr-199-Glu-106 hydrogen-bond network in human carbonic anhydrase II. Proteins. 1993 Sep;17(1):93-106.</reference_text>
      <pubmed_id>7901850</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hakansson K, Wehnert A, Liljas A: X-ray analysis of metal-substituted human carbonic anhydrase II derivatives. Acta Crystallogr D Biol Crystallogr. 1994 Jan 1;50(Pt 1):93-100.</reference_text>
      <pubmed_id>15299481</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hakansson K, Briand C, Zaitsev V, Xue Y, Liljas A: Wild-type and E106Q mutant carbonic anhydrase complexed with acetate.  Acta Crystallogr D Biol Crystallogr. 1994 Jan 1;50(Pt 1):101-4.</reference_text>
      <pubmed_id>15299482</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ippolito JA, Christianson DW: Structural consequences of redesigning a protein-zinc binding site.  Biochemistry. 1994 Dec 27;33(51):15241-9.</reference_text>
      <pubmed_id>7803386</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hakansson K, Liljas A: The structure of a complex between carbonic anhydrase II and a new inhibitor, trifluoromethane sulphonamide. FEBS Lett. 1994 Aug 22;350(2-3):319-22.</reference_text>
      <pubmed_id>8070585</pubmed_id>
    </reference>
    <reference>
      <reference_text>Smith GM, Alexander RS, Christianson DW, McKeever BM, Ponticello GS, Springer JP, Randall WC, Baldwin JJ, Habecker CN: Positions of His-64 and a bound water in human carbonic anhydrase II upon binding three structurally related inhibitors. Protein Sci. 1994 Jan;3(1):118-25.</reference_text>
      <pubmed_id>8142888</pubmed_id>
    </reference>
    <reference>
      <reference_text>Nair SK, Krebs JF, Christianson DW, Fierke CA: Structural basis of inhibitor affinity to variants of human carbonic anhydrase II. Biochemistry. 1995 Mar 28;34(12):3981-9.</reference_text>
      <pubmed_id>7696263</pubmed_id>
    </reference>
    <reference>
      <reference_text>Boriack PA, Christianson DW, Kingery-Wood J, Whitesides GM: Secondary interactions significantly removed from the sulfonamide binding pocket of carbonic anhydrase II influence inhibitor binding constants. J Med Chem. 1995 Jun 23;38(13):2286-91.</reference_text>
      <pubmed_id>7608893</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ippolito JA, Baird TT Jr, McGee SA, Christianson DW, Fierke CA: Structure-assisted redesign of a protein-zinc-binding site with femtomolar affinity. Proc Natl Acad Sci U S A. 1995 May 23;92(11):5017-21.</reference_text>
      <pubmed_id>7761440</pubmed_id>
    </reference>
    <reference>
      <reference_text>Huang CC, Lesburg CA, Kiefer LL, Fierke CA, Christianson DW: Reversal of the hydrogen bond to zinc ligand histidine-119 dramatically diminishes catalysis and enhances metal equilibration kinetics in carbonic anhydrase II. Biochemistry. 1996 Mar 19;35(11):3439-46.</reference_text>
      <pubmed_id>8639494</pubmed_id>
    </reference>
    <reference>
      <reference_text>Scolnick LR, Christianson DW: X-ray crystallographic studies of alanine-65 variants of carbonic anhydrase II reveal the structural basis of compromised proton transfer in catalysis. Biochemistry. 1996 Dec 24;35(51):16429-34.</reference_text>
      <pubmed_id>8987974</pubmed_id>
    </reference>
    <reference>
      <reference_text>Nair SK, Elbaum D, Christianson DW: Unexpected binding mode of the sulfonamide fluorophore 5-dimethylamino-1-naphthalene sulfonamide to human carbonic anhydrase II. Implications for the development of a zinc biosensor. J Biol Chem. 1996 Jan 12;271(2):1003-7.</reference_text>
      <pubmed_id>8557623</pubmed_id>
    </reference>
    <reference>
      <reference_text>Briganti F, Mangani S, Orioli P, Scozzafava A, Vernaglione G, Supuran CT: Carbonic anhydrase activators: X-ray crystallographic and spectroscopic investigations for the interaction of isozymes I and II with histamine. Biochemistry. 1997 Aug 26;36(34):10384-92.</reference_text>
      <pubmed_id>9265618</pubmed_id>
    </reference>
    <reference>
      <reference_text>Lesburg CA, Huang C, Christianson DW, Fierke CA: Histidine --&amp;gt; carboxamide ligand substitutions in the zinc binding site of carbonic anhydrase II alter metal coordination geometry but retain catalytic activity. Biochemistry. 1997 Dec 16;36(50):15780-91.</reference_text>
      <pubmed_id>9398308</pubmed_id>
    </reference>
    <reference>
      <reference_text>Stams T, Chen Y, Boriack-Sjodin PA, Hurt JD, Liao J, May JA, Dean T, Laipis P, Silverman DN, Christianson DW: Structures of murine carbonic anhydrase IV and human carbonic anhydrase II complexed with brinzolamide: molecular basis of isozyme-drug discrimination. Protein Sci. 1998 Mar;7(3):556-63.</reference_text>
      <pubmed_id>9541386</pubmed_id>
    </reference>
    <reference>
      <reference_text>Boriack-Sjodin PA, Zeitlin S, Chen HH, Crenshaw L, Gross S, Dantanarayana A, Delgado P, May JA, Dean T, Christianson DW: Structural analysis of inhibitor binding to human carbonic anhydrase II.  Protein Sci. 1998 Dec;7(12):2483-9.</reference_text>
      <pubmed_id>9865942</pubmed_id>
    </reference>
    <reference>
      <reference_text>Briganti F, Mangani S, Scozzafava A, Vernaglione G, Supuran CT: Carbonic anhydrase catalyzes cyanamide hydration to urea: is it mimicking the physiological reaction? J Biol Inorg Chem. 1999 Oct;4(5):528-36.</reference_text>
      <pubmed_id>10550681</pubmed_id>
    </reference>
    <reference>
      <reference_text>Guerri A, Briganti F, Scozzafava A, Supuran CT, Mangani S: Mechanism of cyanamide hydration catalyzed by carbonic anhydrase II suggested by cryogenic X-ray diffraction. Biochemistry. 2000 Oct 10;39(40):12391-7.</reference_text>
      <pubmed_id>11015219</pubmed_id>
    </reference>
    <reference>
      <reference_text>Cox JD, Hunt JA, Compher KM, Fierke CA, Christianson DW: Structural influence of hydrophobic core residues on metal binding and specificity in carbonic anhydrase II. Biochemistry. 2000 Nov 14;39(45):13687-94.</reference_text>
      <pubmed_id>11076507</pubmed_id>
    </reference>
    <reference>
      <reference_text>Duda D, Tu C, Qian M, Laipis P, Agbandje-McKenna M, Silverman DN, McKenna R: Structural and kinetic analysis of the chemical rescue of the proton transfer function of carbonic anhydrase II. Biochemistry. 2001 Feb 13;40(6):1741-8.</reference_text>
      <pubmed_id>11327835</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kim CY, Chandra PP, Jain A, Christianson DW: Fluoroaromatic-fluoroaromatic interactions between inhibitors bound in the crystal lattice of human carbonic anhydrase II. J Am Chem Soc. 2001 Oct 3;123(39):9620-7.</reference_text>
      <pubmed_id>11572683</pubmed_id>
    </reference>
    <reference>
      <reference_text>Recacha R, Costanzo MJ, Maryanoff BE, Chattopadhyay D: Crystal structure of human carbonic anhydrase II complexed with an anti-convulsant sugar sulphamate. Biochem J. 2002 Feb 1;361(Pt 3):437-41.</reference_text>
      <pubmed_id>11802772</pubmed_id>
    </reference>
    <reference>
      <reference_text>Huang S, Sjoblom B, Sauer-Eriksson AE, Jonsson BH: Organization of an efficient carbonic anhydrase: implications for the mechanism based on structure-function studies of a T199P/C206S mutant. Biochemistry. 2002 Jun 18;41(24):7628-35.</reference_text>
      <pubmed_id>12056894</pubmed_id>
    </reference>
    <reference>
      <reference_text>Tu C, Qian M, An H, Wadhwa NR, Duda D, Yoshioka C, Pathak Y, McKenna R, Laipis PJ, Silverman DN: Kinetic analysis of multiple proton shuttles in the active site of human carbonic anhydrase. J Biol Chem. 2002 Oct 11;277(41):38870-6. Epub 2002 Aug 8.</reference_text>
      <pubmed_id>12171926</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kim CY, Whittington DA, Chang JS, Liao J, May JA, Christianson DW: Structural aspects of isozyme selectivity in the binding of inhibitors to carbonic anhydrases II and IV. J Med Chem. 2002 Feb 14;45(4):888-93.</reference_text>
      <pubmed_id>11831900</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gruneberg S, Stubbs MT, Klebe G: Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation. J Med Chem. 2002 Aug 15;45(17):3588-602.</reference_text>
      <pubmed_id>12166932</pubmed_id>
    </reference>
    <reference>
      <reference_text>Grzybowski BA, Ishchenko AV, Kim CY, Topalov G, Chapman R, Christianson DW, Whitesides GM, Shakhnovich EI: Combinatorial computational method gives new picomolar ligands for a known enzyme. Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1270-3. Epub 2002 Jan 29.</reference_text>
      <pubmed_id>11818565</pubmed_id>
    </reference>
    <reference>
      <reference_text>Duda D, Govindasamy L, Agbandje-McKenna M, Tu C, Silverman DN, McKenna R: The refined atomic structure of carbonic anhydrase II at 1.05 A resolution: implications of chemical rescue of proton transfer. Acta Crystallogr D Biol Crystallogr. 2003 Jan;59(Pt 1):93-104. Epub 2002       Dec 19.</reference_text>
      <pubmed_id>12499545</pubmed_id>
    </reference>
    <reference>
      <reference_text>Weber A, Casini A, Heine A, Kuhn D, Supuran CT, Scozzafava A, Klebe G: Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J Med Chem. 2004 Jan 29;47(3):550-7.</reference_text>
      <pubmed_id>14736236</pubmed_id>
    </reference>
    <reference>
      <reference_text>Lloyd MD, Pederick RL, Natesh R, Woo LW, Purohit A, Reed MJ, Acharya KR, Potter BV: Crystal structure of human carbonic anhydrase II at 1.95 A resolution in complex with 667-coumate, a novel anti-cancer agent. Biochem J. 2005 Feb 1;385(Pt 3):715-20.</reference_text>
      <pubmed_id>15453828</pubmed_id>
    </reference>
    <reference>
      <reference_text>Fisher Z, Hernandez Prada JA, Tu C, Duda D, Yoshioka C, An H, Govindasamy L, Silverman DN, McKenna R: Structural and kinetic characterization of active-site histidine as a proton shuttle in catalysis by human carbonic anhydrase II. Biochemistry. 2005 Feb 1;44(4):1097-105.</reference_text>
      <pubmed_id>15667203</pubmed_id>
    </reference>
    <reference>
      <reference_text>Lloyd MD, Thiyagarajan N, Ho YT, Woo LW, Sutcliffe OB, Purohit A, Reed MJ, Acharya KR, Potter BV: First crystal structures of human carbonic anhydrase II in complex with dual aromatase-steroid sulfatase inhibitors. Biochemistry. 2005 May 10;44(18):6858-66.</reference_text>
      <pubmed_id>15865431</pubmed_id>
    </reference>
    <reference>
      <reference_text>Temperini C, Scozzafava A, Puccetti L, Supuran CT: Carbonic anhydrase activators: X-ray crystal structure of the adduct of human isozyme II with L-histidine as a platform for the design of stronger activators. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5136-41. Epub 2005 Oct 7.</reference_text>
      <pubmed_id>16214338</pubmed_id>
    </reference>
    <reference>
      <reference_text>Menchise V, De Simone G, Alterio V, Di Fiore A, Pedone C, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: stacking with Phe131 determines active site binding region of inhibitors as exemplified by the X-ray crystal structure of a membrane-impermeant antitumor sulfonamide complexed with isozyme II. J Med Chem. 2005 Sep 8;48(18):5721-7.</reference_text>
      <pubmed_id>16134940</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bhatt D, Tu C, Fisher SZ, Hernandez Prada JA, McKenna R, Silverman DN: Proton transfer in a Thr200His mutant of human carbonic anhydrase II.  Proteins. 2005 Nov 1;61(2):239-45.</reference_text>
      <pubmed_id>16106378</pubmed_id>
    </reference>
    <reference>
      <reference_text>Budayova-Spano M, Fisher SZ, Dauvergne MT, Agbandje-McKenna M, Silverman DN, Myles DA, McKenna R: Production and X-ray crystallographic analysis of fully deuterated human carbonic anhydrase II. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2006 Jan 1;62(Pt 1):6-9.       Epub 2005 Dec 16.</reference_text>
      <pubmed_id>16511248</pubmed_id>
    </reference>
    <reference>
      <reference_text>Fisher SZ, Govindasamy L, Boyle N, Agbandje-McKenna M, Silverman DN, Blackburn GM, McKenna R: X-ray crystallographic studies reveal that the incorporation of spacer groups in carbonic anhydrase inhibitors causes alternate binding modes. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2006 Jul 1;62(Pt       7):618-22. Epub 2006 Jun 10.</reference_text>
      <pubmed_id>16820676</pubmed_id>
    </reference>
    <reference>
      <reference_text>Di Fiore A, Pedone C, D'Ambrosio K, Scozzafava A, De Simone G, Supuran CT: Carbonic anhydrase inhibitors: Valdecoxib binds to a different active site region of the human isoform II as compared to the structurally related cyclooxygenase II &amp;quot;selective&amp;quot; inhibitor celecoxib. Bioorg Med Chem Lett. 2006 Jan 15;16(2):437-42. Epub 2005 Nov 14.</reference_text>
      <pubmed_id>16290146</pubmed_id>
    </reference>
    <reference>
      <reference_text>Temperini C, Innocenti A, Scozzafava A, Supuran CT: N-hydroxyurea--a versatile zinc binding function in the design of metalloenzyme inhibitors. Bioorg Med Chem Lett. 2006 Aug 15;16(16):4316-20. Epub 2006 Jun 12.</reference_text>
      <pubmed_id>16759856</pubmed_id>
    </reference>
    <reference>
      <reference_text>Menchise V, De Simone G, Di Fiore A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: X-ray crystallographic studies for the binding of 5-amino-1,3,4-thiadiazole-2-sulfonamide and 5-(4-amino-3-chloro-5-fluorophenylsulfonamido)-1,3,4-thiadiazole-2-sulfona mide to human isoform II. Bioorg Med Chem Lett. 2006 Dec 15;16(24):6204-8. Epub 2006 Sep 26.</reference_text>
      <pubmed_id>17000110</pubmed_id>
    </reference>
    <reference>
      <reference_text>Temperini C, Scozzafava A, Vullo D, Supuran CT: Carbonic anhydrase activators. Activation of isozymes I, II, IV, VA, VII, and XIV with l- and d-histidine and crystallographic analysis of their adducts with isoform II: engineering proton-transfer processes within the active site of an enzyme. Chemistry. 2006 Sep 18;12(27):7057-66.</reference_text>
      <pubmed_id>16807956</pubmed_id>
    </reference>
    <reference>
      <reference_text>Jude KM, Banerjee AL, Haldar MK, Manokaran S, Roy B, Mallik S, Srivastava DK, Christianson DW: Ultrahigh resolution crystal structures of human carbonic anhydrases I and II complexed with &amp;quot;two-prong&amp;quot; inhibitors reveal the molecular basis of high affinity. J Am Chem Soc. 2006 Mar 8;128(9):3011-8.</reference_text>
      <pubmed_id>16506782</pubmed_id>
    </reference>
    <reference>
      <reference_text>Alterio V, Vitale RM, Monti SM, Pedone C, Scozzafava A, Cecchi A, De Simone G, Supuran CT: Carbonic anhydrase inhibitors: X-ray and molecular modeling study for the interaction of a fluorescent antitumor sulfonamide with isozyme II and IX. J Am Chem Soc. 2006 Jun 28;128(25):8329-35.</reference_text>
      <pubmed_id>16787097</pubmed_id>
    </reference>
    <reference>
      <reference_text>Temperini C, Scozzafava A, Vullo D, Supuran CT: Carbonic anhydrase activators. Activation of isoforms I, II, IV, VA, VII, and XIV with L- and D-phenylalanine and crystallographic analysis of their adducts with isozyme II: stereospecific recognition within the active site of an enzyme and its consequences for the drug design. J Med Chem. 2006 May 18;49(10):3019-27.</reference_text>
      <pubmed_id>16686544</pubmed_id>
    </reference>
    <reference>
      <reference_text>De Simone G, Vitale RM, Di Fiore A, Pedone C, Scozzafava A, Montero JL, Winum JY, Supuran CT: Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX. J Med Chem. 2006 Sep 7;49(18):5544-51.</reference_text>
      <pubmed_id>16942027</pubmed_id>
    </reference>
    <reference>
      <reference_text>Winum JY, Temperini C, El Cheikh K, Innocenti A, Vullo D, Ciattini S, Montero JL, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: clash with Ala65 as a means for designing inhibitors with low affinity for the ubiquitous isozyme II, exemplified by the crystal structure of the topiramate sulfamide analogue. J Med Chem. 2006 Nov 30;49(24):7024-31.</reference_text>
      <pubmed_id>17125255</pubmed_id>
    </reference>
    <reference>
      <reference_text>Leese MP, Leblond B, Smith A, Newman SP, Di Fiore A, De Simone G, Supuran CT, Purohit A, Reed MJ, Potter BV: 2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. J Med Chem. 2006 Dec 28;49(26):7683-96.</reference_text>
      <pubmed_id>17181151</pubmed_id>
    </reference>
    <reference>
      <reference_text>Kohler K, Hillebrecht A, Schulze Wischeler J, Innocenti A, Heine A, Supuran CT, Klebe G: Saccharin inhibits carbonic anhydrases: possible explanation for its unpleasant metallic aftertaste. Angew Chem Int Ed Engl. 2007;46(40):7697-9.</reference_text>
      <pubmed_id>17705204</pubmed_id>
    </reference>
    <reference>
      <reference_text>Fisher SZ, Maupin CM, Budayova-Spano M, Govindasamy L, Tu C, Agbandje-McKenna M, Silverman DN, Voth GA, McKenna R: Atomic crystal and molecular dynamics simulation structures of human carbonic anhydrase II: insights into the proton transfer mechanism. Biochemistry. 2007 Mar 20;46(11):2930-7. Epub 2007 Feb 24.</reference_text>
      <pubmed_id>17319692</pubmed_id>
    </reference>
    <reference>
      <reference_text>Fisher SZ, Tu C, Bhatt D, Govindasamy L, Agbandje-McKenna M, McKenna R, Silverman DN: Speeding up proton transfer in a fast enzyme: kinetic and crystallographic studies on the effect of hydrophobic amino acid substitutions in the active site of human carbonic anhydrase II. Biochemistry. 2007 Mar 27;46(12):3803-13. Epub 2007 Mar 2.</reference_text>
      <pubmed_id>17330962</pubmed_id>
    </reference>
    <reference>
      <reference_text>Temperini C, Innocenti A, Scozzafava A, Mastrolorenzo A, Supuran CT: Carbonic anhydrase activators: L-Adrenaline plugs the active site entrance of isozyme II, activating better isoforms I, IV, VA, VII, and XIV. Bioorg Med Chem Lett. 2007 Feb 1;17(3):628-35. Epub 2006 Nov 15.</reference_text>
      <pubmed_id>17127057</pubmed_id>
    </reference>
    <reference>
      <reference_text>Di Fiore A, Scozzafava A, Winum JY, Montero JL, Pedone C, Supuran CT, De Simone G: Carbonic anhydrase inhibitors: binding of an antiglaucoma glycosyl-sulfanilamide derivative to human isoform II and its consequences for the drug design of enzyme inhibitors incorporating sugar moieties. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1726-31. Epub 2007 Jan 8.</reference_text>
      <pubmed_id>17251017</pubmed_id>
    </reference>
    <reference>
      <reference_text>Temperini C, Winum JY, Montero JL, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: the X-ray crystal structure of the adduct of N-hydroxysulfamide with isozyme II explains why this new zinc binding function is effective in the design of potent inhibitors. Bioorg Med Chem Lett. 2007 May 15;17(10):2795-801. Epub 2007 Feb 28.</reference_text>
      <pubmed_id>17346964</pubmed_id>
    </reference>
    <reference>
      <reference_text>Alterio V, De Simone G, Monti SM, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: inhibition of human, bacterial, and archaeal isozymes with benzene-1,3-disulfonamides--solution and crystallographic studies. Bioorg Med Chem Lett. 2007 Aug 1;17(15):4201-7. Epub 2007 May 18.</reference_text>
      <pubmed_id>17540563</pubmed_id>
    </reference>
    <reference>
      <reference_text>Temperini C, Innocenti A, Mastrolorenzo A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Interaction of the antiepileptic drug sulthiame with twelve mammalian isoforms: kinetic and X-ray crystallographic studies. Bioorg Med Chem Lett. 2007 Sep 1;17(17):4866-72. Epub 2007 Jun 14.</reference_text>
      <pubmed_id>17588751</pubmed_id>
    </reference>
    <reference>
      <reference_text>Bhatt D, Fisher SZ, Tu C, McKenna R, Silverman DN: Location of binding sites in small molecule rescue of human carbonic anhydrase II. Biophys J. 2007 Jan 15;92(2):562-70. Epub 2006 Oct 27.</reference_text>
      <pubmed_id>17071654</pubmed_id>
    </reference>
    <reference>
      <reference_text>Srivastava DK, Jude KM, Banerjee AL, Haldar M, Manokaran S, Kooren J, Mallik S, Christianson DW: Structural analysis of charge discrimination in the binding of inhibitors to human carbonic anhydrases I and II. J Am Chem Soc. 2007 May 2;129(17):5528-37. Epub 2007 Apr 4.</reference_text>
      <pubmed_id>17407288</pubmed_id>
    </reference>
    <reference>
      <reference_text>Barrese AA 3rd, Genis C, Fisher SZ, Orwenyo JN, Kumara MT, Dutta SK, Phillips E, Kiddle JJ, Tu C, Silverman DN, Govindasamy L, Agbandje-McKenna M, McKenna R, Tripp BC: Inhibition of carbonic anhydrase II by thioxolone: a mechanistic and structural study. Biochemistry. 2008 Mar 11;47(10):3174-84. Epub 2008 Feb 12.</reference_text>
      <pubmed_id>18266323</pubmed_id>
    </reference>
    <reference>
      <reference_text>Zheng J, Avvaru BS, Tu C, McKenna R, Silverman DN: Role of hydrophilic residues in proton transfer during catalysis by human carbonic anhydrase II. Biochemistry. 2008 Nov 18;47(46):12028-36. Epub 2008 Oct 23.</reference_text>
      <pubmed_id>18942852</pubmed_id>
    </reference>
    <reference>
      <reference_text>Guzel O, Temperini C, Innocenti A, Scozzafava A, Salman A, Supuran CT: Carbonic anhydrase inhibitors. Interaction of 2-(hydrazinocarbonyl)-3-phenyl-1H-indole-5-sulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies. Bioorg Med Chem Lett. 2008 Jan 1;18(1):152-8. Epub 2007 Nov 4.</reference_text>
      <pubmed_id>18024029</pubmed_id>
    </reference>
    <reference>
      <reference_text>Temperini C, Cecchi A, Boyle NA, Scozzafava A, Cabeza JE, Wentworth P Jr, Blackburn GM, Supuran CT: Carbonic anhydrase inhibitors. Interaction of 2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies. Bioorg Med Chem Lett. 2008 Feb 1;18(3):999-1005. Epub 2007 Dec 15.</reference_text>
      <pubmed_id>18162396</pubmed_id>
    </reference>
    <reference>
      <reference_text>Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct. Bioorg Med Chem Lett. 2008 Apr 15;18(8):2567-73. Epub 2008 Mar 20.</reference_text>
      <pubmed_id>18374572</pubmed_id>
    </reference>
    <reference>
      <reference_text>Di Fiore A, Pedone C, Antel J, Waldeck H, Witte A, Wurl M, Scozzafava A, Supuran CT, De Simone G: Carbonic anhydrase inhibitors: the X-ray crystal structure of ethoxzolamide complexed to human isoform II reveals the importance of thr200 and gln92 for obtaining tight-binding inhibitors. Bioorg Med Chem Lett. 2008 Apr 15;18(8):2669-74. Epub 2008 Mar 18.</reference_text>
      <pubmed_id>18359629</pubmed_id>
    </reference>
    <reference>
      <reference_text>Temperini C, Innocenti A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-ray crystallographic studies. Bioorg Med Chem Lett. 2008 Aug 1;18(15):4282-6. Epub 2008 Jul 5.</reference_text>
      <pubmed_id>18640037</pubmed_id>
    </reference>
    <reference>
      <reference_text>D'Ambrosio K, Masereel B, Thiry A, Scozzafava A, Supuran CT, De Simone G: Carbonic anhydrase inhibitors: binding of indanesulfonamides to the human isoform II. ChemMedChem. 2008 Mar;3(3):473-7.</reference_text>
      <pubmed_id>18161740</pubmed_id>
    </reference>
    <reference>
      <reference_text>Aaron JA, Chambers JM, Jude KM, Di Costanzo L, Dmochowski IJ, Christianson DW: Structure of a 129Xe-cryptophane biosensor complexed with human carbonic anhydrase II. J Am Chem Soc. 2008 Jun 4;130(22):6942-3. Epub 2008 May 8.</reference_text>
      <pubmed_id>18461940</pubmed_id>
    </reference>
    <reference>
      <reference_text>Domsic JF, Avvaru BS, Kim CU, Gruner SM, Agbandje-McKenna M, Silverman DN, McKenna R: Entrapment of carbon dioxide in the active site of carbonic anhydrase II.  J Biol Chem. 2008 Nov 7;283(45):30766-71. Epub 2008 Sep 2.</reference_text>
      <pubmed_id>18768466</pubmed_id>
    </reference>
    <reference>
      <reference_text>Leese MP, Jourdan FL, Gaukroger K, Mahon MF, Newman SP, Foster PA, Stengel C, Regis-Lydi S, Ferrandis E, Di Fiore A, De Simone G, Supuran CT, Purohit A, Reed MJ, Potter BV: Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents. J Med Chem. 2008 Mar 13;51(5):1295-308. Epub 2008 Feb 9.</reference_text>
      <pubmed_id>18260615</pubmed_id>
    </reference>
    <reference>
      <reference_text>D'Ambrosio K, Vitale RM, Dogne JM, Masereel B, Innocenti A, Scozzafava A, De Simone G, Supuran CT: Carbonic anhydrase inhibitors: bioreductive nitro-containing sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII. J Med Chem. 2008 Jun 12;51(11):3230-7. Epub 2008 May 16.</reference_text>
      <pubmed_id>18481843</pubmed_id>
    </reference>
    <reference>
      <reference_text>Woo LW, Fischer DS, Sharland CM, Trusselle M, Foster PA, Chander SK, Di Fiore A, Supuran CT, De Simone G, Purohit A, Reed MJ, Potter BV: Anticancer steroid sulfatase inhibitors: synthesis of a potent fluorinated second-generation agent, in vitro and in vivo activities, molecular modeling, and protein crystallography. Mol Cancer Ther. 2008 Aug;7(8):2435-44.</reference_text>
      <pubmed_id>18723489</pubmed_id>
    </reference>
    <reference>
      <reference_text>Genis C, Sippel KH, Case N, Cao W, Avvaru BS, Tartaglia LJ, Govindasamy L, Tu C, Agbandje-McKenna M, Silverman DN, Rosser CJ, McKenna R: Design of a carbonic anhydrase IX active-site mimic to screen inhibitors for possible anticancer properties. Biochemistry. 2009 Feb 17;48(6):1322-31.</reference_text>
      <pubmed_id>19170619</pubmed_id>
    </reference>
    <reference>
      <reference_text>Avvaru BS, Busby SA, Chalmers MJ, Griffin PR, Venkatakrishnan B, Agbandje-McKenna M, Silverman DN, McKenna R: Apo-human carbonic anhydrase II revisited: implications of the loss of a metal in protein structure, stability, and solvent network. Biochemistry. 2009 Aug 11;48(31):7365-72.</reference_text>
      <pubmed_id>19583303</pubmed_id>
    </reference>
    <reference>
      <reference_text>Crocetti L, Maresca A, Temperini C, Hall RA, Scozzafava A, Muhlschlegel FA, Supuran CT: A thiabendazole sulfonamide shows potent inhibitory activity against mammalian and nematode alpha-carbonic anhydrases. Bioorg Med Chem Lett. 2009 Mar 1;19(5):1371-5. Epub 2009 Jan 19.</reference_text>
      <pubmed_id>19186056</pubmed_id>
    </reference>
    <reference>
      <reference_text>Maresca A, Temperini C, Vu H, Pham NB, Poulsen SA, Scozzafava A, Quinn RJ, Supuran CT: Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc. 2009 Mar 4;131(8):3057-62.</reference_text>
      <pubmed_id>19206230</pubmed_id>
    </reference>
    <reference>
      <reference_text>Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone and indapamide X-ray crystal structures in adducts with isozyme II: when three water molecules and the keto-enol tautomerism make the difference. J Med Chem. 2009 Jan 22;52(2):322-8.</reference_text>
      <pubmed_id>19115843</pubmed_id>
    </reference>
    <reference>
      <reference_text>Vitale RM, Alterio V, Innocenti A, Winum JY, Monti SM, De Simone G, Supuran CT: Carbonic anhydrase inhibitors. Comparison of aliphatic sulfamate/bis-sulfamate adducts with isozymes II and IX as a platform for designing tight-binding, more isoform-selective inhibitors. J Med Chem. 2009 Oct 8;52(19):5990-8.</reference_text>
      <pubmed_id>19731956</pubmed_id>
    </reference>
    <reference>
      <reference_text>Lopez M, Paul B, Hofmann A, Morizzi J, Wu QK, Charman SA, Innocenti A, Vullo D, Supuran CT, Poulsen SA: S-glycosyl primary sulfonamides--a new structural class for selective inhibition of cancer-associated carbonic anhydrases. J Med Chem. 2009 Oct 22;52(20):6421-32.</reference_text>
      <pubmed_id>19827837</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ciani L, Cecchi A, Temperini C, Supuran CT, Ristori S: Dissecting the inhibition mechanism of cytosolic versus transmembrane carbonic anhydrases by ESR. J Phys Chem B. 2009 Oct 22;113(42):13998-4005.</reference_text>
      <pubmed_id>19778001</pubmed_id>
    </reference>
    <reference>
      <reference_text>Sjoblom B, Polentarutti M, Djinovic-Carugo K: Structural study of X-ray induced activation of carbonic anhydrase.  Proc Natl Acad Sci U S A. 2009 Jun 30;106(26):10609-13. Epub 2009 Jun 11.</reference_text>
      <pubmed_id>19520834</pubmed_id>
    </reference>
    <reference>
      <reference_text>Jones GL, Sofro AS, Shaw DC: Chemical and enzymological characterization of an Indonesian variant of human erythrocyte carbonic anhydrase II, CAII Jogjakarta (17 Lys leads to Glu). Biochem Genet. 1982 Oct;20(9-10):979-1000.</reference_text>
      <pubmed_id>6817747</pubmed_id>
    </reference>
    <reference>
      <reference_text>Jones GL, Shaw DC: A chemical and enzymological comparison of the common major human erythrocyte carbonic anhydrase II, its minor component, and a new genetic variant, CA II Melbourne (237 Pro leads to His). Hum Genet. 1983;63(4):392-9.</reference_text>
      <pubmed_id>6407977</pubmed_id>
    </reference>
    <reference>
      <reference_text>Venta PJ, Welty RJ, Johnson TM, Sly WS, Tashian RE: Carbonic anhydrase II deficiency syndrome in a Belgian family is caused by a point mutation at an invariant histidine residue (107 His----Tyr): complete structure of the normal human CA II gene. Am J Hum Genet. 1991 Nov;49(5):1082-90.</reference_text>
      <pubmed_id>1928091</pubmed_id>
    </reference>
    <reference>
      <reference_text>Roth DE, Venta PJ, Tashian RE, Sly WS: Molecular basis of human carbonic anhydrase II deficiency.  Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1804-8.</reference_text>
      <pubmed_id>1542674</pubmed_id>
    </reference>
    <reference>
      <reference_text>Soda H, Yukizane S, Yoshida I, Koga Y, Aramaki S, Kato H: A point mutation in exon 3 (His 107--&amp;gt;Tyr) in two unrelated Japanese patients with carbonic anhydrase II deficiency with central nervous system involvement. Hum Genet. 1996 Apr;97(4):435-7.</reference_text>
      <pubmed_id>8834238</pubmed_id>
    </reference>
    <reference>
      <reference_text>Hu PY, Lim EJ, Ciccolella J, Strisciuglio P, Sly WS: Seven novel mutations in carbonic anhydrase II deficiency syndrome identified by SSCP and direct sequencing analysis. Hum Mutat. 1997;9(5):383-7.</reference_text>
      <pubmed_id>9143915</pubmed_id>
    </reference>
    <reference>
      <reference_text>Shah GN, Bonapace G, Hu PY, Strisciuglio P, Sly WS: Carbonic anhydrase II deficiency syndrome (osteopetrosis with renal tubular acidosis and brain calcification): novel mutations in CA2 identified by direct sequencing expand the opportunity for genotype-phenotype correlation. Hum Mutat. 2004 Sep;24(3):272.</reference_text>
      <pubmed_id>15300855</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Methyclothiazide</name>
        <accession>HMDB14377</accession>
      </metabolite>
      <reference>
        <reference_text>Meyerson LR, Nesta D: [3H]acetazolamide binding to carbonic anhydrase in normal and transformed cells.  Biochem Pharmacol. 1991 Mar 15-Apr 1;41(6-7):995-1000.</reference_text>
        <pubmed_id>1901209</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methyclothiazide</name>
        <accession>HMDB14377</accession>
      </metabolite>
      <reference>
        <reference_text>Schaeffer P, Vigne P, Frelin C, Lazdunski M: Identification and pharmacological properties of binding sites for the atypical thiazide diuretic, indapamide. Eur J Pharmacol. 1990 Jul 17;182(3):503-8.</reference_text>
        <pubmed_id>2226620</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methyclothiazide</name>
        <accession>HMDB14377</accession>
      </metabolite>
      <reference>
        <reference_text>Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. Epub 2008 Dec 24.</reference_text>
        <pubmed_id>19119014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethoxzolamide</name>
        <accession>HMDB14456</accession>
      </metabolite>
      <reference>
        <reference_text>Mincione F, Scozzafava A, Supuran CT: The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. Curr Pharm Des. 2008;14(7):649-54.</reference_text>
        <pubmed_id>18336310</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bendroflumethiazide</name>
        <accession>HMDB14580</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Bendroflumethiazide</name>
        <accession>HMDB14580</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Benzthiazide</name>
        <accession>HMDB14702</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Benzthiazide</name>
        <accession>HMDB14702</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Benzthiazide</name>
        <accession>HMDB14702</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cyclothiazide</name>
        <accession>HMDB14744</accession>
      </metabolite>
      <reference>
        <reference_text>Liljequist S, Cebers G, Kalda A: Effects of decahydroisoquinoline-3-carboxylic acid monohydrate, a novel AMPA receptor antagonist, on glutamate-induced CA2+ responses and neurotoxicity in rat cortical and cerebellar granule neurons. Biochem Pharmacol. 1995 Nov 27;50(11):1761-74.</reference_text>
        <pubmed_id>8615854</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Cyclothiazide</name>
        <accession>HMDB14744</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Furosemide</name>
        <accession>HMDB01933</accession>
      </metabolite>
      <reference>
        <reference_text>Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank.  Nucleic Acids Res. 2000 Jan 1;28(1):235-42.</reference_text>
        <pubmed_id>10592235</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Methazolamide</name>
        <accession>HMDB14841</accession>
      </metabolite>
      <reference>
        <reference_text>Mincione F, Scozzafava A, Supuran CT: The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. Curr Pharm Des. 2008;14(7):649-54.</reference_text>
        <pubmed_id>18336310</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroflumethiazide</name>
        <accession>HMDB14912</accession>
      </metabolite>
      <reference>
        <reference_text>Schaeffer P, Vigne P, Frelin C, Lazdunski M: Identification and pharmacological properties of binding sites for the atypical thiazide diuretic, indapamide. Eur J Pharmacol. 1990 Jul 17;182(3):503-8.</reference_text>
        <pubmed_id>2226620</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Hydroflumethiazide</name>
        <accession>HMDB14912</accession>
      </metabolite>
      <reference>
        <reference_text>Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. Epub 2008 Dec 24.</reference_text>
        <pubmed_id>19119014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Acetazolamide</name>
        <accession>HMDB14957</accession>
      </metabolite>
      <reference>
        <reference_text>Avvaru BS, Wagner JM, Maresca A, Scozzafava A, Robbins AH, Supuran CT, McKenna R: Carbonic anhydrase inhibitors. The X-ray crystal structure of human isoform II in adduct with an adamantyl analogue of acetazolamide resides in a less utilized binding pocket than most hydrophobic inhibitors. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4376-81. Epub 2010 Jun 17.</reference_text>
        <pubmed_id>20605094</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Acetazolamide</name>
        <accession>HMDB14957</accession>
      </metabolite>
      <reference>
        <reference_text>Mincione F, Scozzafava A, Supuran CT: The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. Curr Pharm Des. 2008;14(7):649-54.</reference_text>
        <pubmed_id>18336310</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dorzolamide</name>
        <accession>HMDB15007</accession>
      </metabolite>
      <reference>
        <reference_text>Lachmann C, Jorg KM, Trinkmann R: [Postoperative behavior of intraocular pressure after posterior Nd:YAG laser capsulotomy--critical evaluation in preventive administration of local carbonic anhydrase II inhibitor dorzolamide hydrochloride (Trusopt)]. Klin Monbl Augenheilkd. 1998 Dec;213(6):326-30.</reference_text>
        <pubmed_id>10048009</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dorzolamide</name>
        <accession>HMDB15007</accession>
      </metabolite>
      <reference>
        <reference_text>Wong BK, Bruhin PJ, Barrish A, Lin JH: Nonlinear dorzolamide pharmacokinetics in rats: concentration-dependent erythrocyte distribution and drug-metabolite displacement interaction. Drug Metab Dispos. 1996 Jun;24(6):659-63.</reference_text>
        <pubmed_id>8781782</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dorzolamide</name>
        <accession>HMDB15007</accession>
      </metabolite>
      <reference>
        <reference_text>Berg JT, Ramanathan S, Gabrielli MG, Swenson ER: Carbonic anhydrase in mammalian vascular smooth muscle.  J Histochem Cytochem. 2004 Aug;52(8):1101-6.</reference_text>
        <pubmed_id>15258186</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dorzolamide</name>
        <accession>HMDB15007</accession>
      </metabolite>
      <reference>
        <reference_text>Hasegawa T, Hara K, Hata S: Binding of dorzolamide and its metabolite, N-deethylated dorzolamide, to human erythrocytes in vitro. Drug Metab Dispos. 1994 May-Jun;22(3):377-82.</reference_text>
        <pubmed_id>8070313</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dorzolamide</name>
        <accession>HMDB15007</accession>
      </metabolite>
      <reference>
        <reference_text>Maren TH, Conroy CW, Wynns GC, Levy NS: Ocular absorption, blood levels, and excretion of dorzolamide, a topically active carbonic anhydrase inhibitor. J Ocul Pharmacol Ther. 1997 Feb;13(1):23-30.</reference_text>
        <pubmed_id>9029437</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dorzolamide</name>
        <accession>HMDB15007</accession>
      </metabolite>
      <reference>
        <reference_text>Sugrue MF: Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Prog Retin Eye Res. 2000 Jan;19(1):87-112.</reference_text>
        <pubmed_id>10614682</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dorzolamide</name>
        <accession>HMDB15007</accession>
      </metabolite>
      <reference>
        <reference_text>Sugrue MF: The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor. J Ocul Pharmacol Ther. 1996 Fall;12(3):363-76.</reference_text>
        <pubmed_id>8875343</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dorzolamide</name>
        <accession>HMDB15007</accession>
      </metabolite>
      <reference>
        <reference_text>Srinivas SP, Ong A, Zhai CB, Bonanno JA: Inhibition of carbonic anhydrase activity in cultured bovine corneal endothelial cells by dorzolamide. Invest Ophthalmol Vis Sci. 2002 Oct;43(10):3273-8.</reference_text>
        <pubmed_id>12356834</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dorzolamide</name>
        <accession>HMDB15007</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorothiazide</name>
        <accession>HMDB15018</accession>
      </metabolite>
      <reference>
        <reference_text>Weiner ID, Verlander JW: Renal and hepatic expression of the ammonium transporter proteins, Rh B Glycoprotein and Rh C Glycoprotein. Acta Physiol Scand. 2003 Dec;179(4):331-8.</reference_text>
        <pubmed_id>14656370</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorothiazide</name>
        <accession>HMDB15018</accession>
      </metabolite>
      <reference>
        <reference_text>Puscas I, Coltau M, Baican M, Pasca R, Domuta G: The inhibitory effect of diuretics on carbonic anhydrases.  Res Commun Mol Pathol Pharmacol. 1999;105(3):213-36.</reference_text>
        <pubmed_id>10954127</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorothiazide</name>
        <accession>HMDB15018</accession>
      </metabolite>
      <reference>
        <reference_text>Verlander JW, Miller RT, Frank AE, Royaux IE, Kim YH, Weiner ID: Localization of the ammonium transporter proteins RhBG and RhCG in mouse kidney.  Am J Physiol Renal Physiol. 2003 Feb;284(2):F323-37. Epub 2002 Oct 8.</reference_text>
        <pubmed_id>12388412</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Chlorothiazide</name>
        <accession>HMDB15018</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>De Simone G, Scozzafava A, Supuran CT: Which carbonic anhydrases are targeted by the antiepileptic sulfonamides and sulfamates? Chem Biol Drug Des. 2009 Sep;74(3):317-21.</reference_text>
        <pubmed_id>19703035</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Supuran CT, Di Fiore A, De Simone G: Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity.  Expert Opin Emerg Drugs. 2008 Jun;13(2):383-92.</reference_text>
        <pubmed_id>18537527</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Shank RP, Smith-Swintosky VL, Maryanoff BE: Carbonic anhydrase inhibition. Insight into the characteristics of zonisamide, topiramate, and the sulfamide cognate of topiramate. J Enzyme Inhib Med Chem. 2008 Apr;23(2):271-6.</reference_text>
        <pubmed_id>18343915</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>De Simone G, Di Fiore A, Menchise V, Pedone C, Antel J, Casini A, Scozzafava A, Wurl M, Supuran CT: Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorg Med Chem Lett. 2005 May 2;15(9):2315-20.</reference_text>
        <pubmed_id>15837316</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Masuda Y, Karasawa T: Inhibitory effect of zonisamide on human carbonic anhydrase in vitro.  Arzneimittelforschung. 1993 Apr;43(4):416-8.</reference_text>
        <pubmed_id>8494570</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Farooq MU, Moore PW, Bhatt A, Aburashed R, Kassab MY: Therapeutic role of zonisamide in neuropsychiatric disorders.  Mini Rev Med Chem. 2008 Sep;8(10):968-75.</reference_text>
        <pubmed_id>18782051</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Temperini C, Cecchi A, Boyle NA, Scozzafava A, Cabeza JE, Wentworth P Jr, Blackburn GM, Supuran CT: Carbonic anhydrase inhibitors. Interaction of 2-N,N-dimethylamino-1,3,4-thiadiazole-5-methanesulfonamide with 12 mammalian isoforms: kinetic and X-ray crystallographic studies. Bioorg Med Chem Lett. 2008 Feb 1;18(3):999-1005. Epub 2007 Dec 15.</reference_text>
        <pubmed_id>18162396</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>Biton V: Clinical pharmacology and mechanism of action of zonisamide.  Clin Neuropharmacol. 2007 Jul-Aug;30(4):230-40.</reference_text>
        <pubmed_id>17762320</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Zonisamide</name>
        <accession>HMDB15045</accession>
      </metabolite>
      <reference>
        <reference_text>[No authors listed]Zonisamide: new drug. No advantage in refractory partial epilepsy.  Prescrire Int. 2007 Jun;16(89):95-7.</reference_text>
        <pubmed_id>17582922</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trichlormethiazide</name>
        <accession>HMDB15156</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trichlormethiazide</name>
        <accession>HMDB15156</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Trichlormethiazide</name>
        <accession>HMDB15156</accession>
      </metabolite>
      <reference>
        <reference_text>Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21. Epub 2008 Dec 24.</reference_text>
        <pubmed_id>19119014</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethinamate</name>
        <accession>HMDB15165</accession>
      </metabolite>
      <reference>
        <reference_text>Parr JS, Khalifah RG: Inhibition of carbonic anhydrases I and II by N-unsubstituted carbamate esters.  J Biol Chem. 1992 Dec 15;267(35):25044-50.</reference_text>
        <pubmed_id>1460006</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Ethinamate</name>
        <accession>HMDB15165</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diazoxide</name>
        <accession>HMDB15251</accession>
      </metabolite>
      <reference>
        <reference_text>Munoz A, Nakazaki M, Goodman JC, Barrios R, Onetti CG, Bryan J, Aguilar-Bryan L: Ischemic preconditioning in the hippocampus of a knockout mouse lacking SUR1-based K(ATP) channels. Stroke. 2003 Jan;34(1):164-70.</reference_text>
        <pubmed_id>12511769</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Diazoxide</name>
        <accession>HMDB15251</accession>
      </metabolite>
      <reference>
        <reference_text>Sekine N, Ullrich S, Regazzi R, Pralong WF, Wollheim CB: Postreceptor signalling of growth hormone and prolactin and their effects in the differentiated insulin-secreting cell line, INS-1. Endocrinology. 1996 May;137(5):1841-50.</reference_text>
        <pubmed_id>8612523</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dichlorphenamide</name>
        <accession>HMDB15275</accession>
      </metabolite>
      <reference>
        <reference_text>Mincione F, Scozzafava A, Supuran CT: The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. Curr Pharm Des. 2008;14(7):649-54.</reference_text>
        <pubmed_id>18336310</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Brinzolamide</name>
        <accession>HMDB15325</accession>
      </metabolite>
      <reference>
        <reference_text>Stams T, Chen Y, Boriack-Sjodin PA, Hurt JD, Liao J, May JA, Dean T, Laipis P, Silverman DN, Christianson DW: Structures of murine carbonic anhydrase IV and human carbonic anhydrase II complexed with brinzolamide: molecular basis of isozyme-drug discrimination. Protein Sci. 1998 Mar;7(3):556-63.</reference_text>
        <pubmed_id>9541386</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Brinzolamide</name>
        <accession>HMDB15325</accession>
      </metabolite>
      <reference>
        <reference_text>DeSantis L: Preclinical overview of brinzolamide.  Surv Ophthalmol. 2000 Jan;44 Suppl 2:S119-29.</reference_text>
        <pubmed_id>10665514</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Brinzolamide</name>
        <accession>HMDB15325</accession>
      </metabolite>
      <reference>
        <reference_text>Winum JY, Casini A, Mincione F, Starnotti M, Montero JL, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors: N-(p-sulfamoylphenyl)-alpha-D-glycopyranosylamines as topically acting antiglaucoma agents in hypertensive rabbits. Bioorg Med Chem Lett. 2004 Jan 5;14(1):225-9.</reference_text>
        <pubmed_id>14684332</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Brinzolamide</name>
        <accession>HMDB15325</accession>
      </metabolite>
      <reference>
        <reference_text>Boriack-Sjodin PA, Zeitlin S, Chen HH, Crenshaw L, Gross S, Dantanarayana A, Delgado P, May JA, Dean T, Christianson DW: Structural analysis of inhibitor binding to human carbonic anhydrase II.  Protein Sci. 1998 Dec;7(12):2483-9.</reference_text>
        <pubmed_id>9865942</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Brinzolamide</name>
        <accession>HMDB15325</accession>
      </metabolite>
      <reference>
        <reference_text>Ilies M, Supuran CT, Scozzafava A, Casini A, Mincione F, Menabuoni L, Caproiu MT, Maganu M, Banciu MD: Carbonic anhydrase inhibitors: sulfonamides incorporating furan-, thiophene- and pyrrole-carboxamido groups possess strong topical intraocular pressure lowering properties as aqueous suspensions. Bioorg Med Chem. 2000 Aug;8(8):2145-55.</reference_text>
        <pubmed_id>11003159</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Brinzolamide</name>
        <accession>HMDB15325</accession>
      </metabolite>
      <reference>
        <reference_text>Iester M: Brinzolamide ophthalmic suspension: a review of its pharmacology and use in the treatment of open angle glaucoma and ocular hypertension. Clin Ophthalmol. 2008 Sep;2(3):517-23.</reference_text>
        <pubmed_id>19668749</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Brinzolamide</name>
        <accession>HMDB15325</accession>
      </metabolite>
      <reference>
        <reference_text>Vullo D, Franchi M, Gallori E, Antel J, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides. J Med Chem. 2004 Feb 26;47(5):1272-9.</reference_text>
        <pubmed_id>14971907</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinethazone</name>
        <accession>HMDB15420</accession>
      </metabolite>
      <reference>
        <reference_text>Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Sulfonamide diuretics revisited--old leads for new applications? Org Biomol Chem. 2008 Jul 21;6(14):2499-506. Epub 2008 May 29.</reference_text>
        <pubmed_id>18600270</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinethazone</name>
        <accession>HMDB15420</accession>
      </metabolite>
      <reference>
        <reference_text>Temperini C, Cecchi A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adduct. Bioorg Med Chem Lett. 2008 Apr 15;18(8):2567-73. Epub 2008 Mar 20.</reference_text>
        <pubmed_id>18374572</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Quinethazone</name>
        <accession>HMDB15420</accession>
      </metabolite>
      <reference>
        <reference_text>Supuran CT: Diuretics: from classical carbonic anhydrase inhibitors to novel applications of the sulfonamides. Curr Pharm Des. 2008;14(7):641-8.</reference_text>
        <pubmed_id>18336309</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Urea</name>
        <accession>HMDB00294</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Urea</name>
        <accession>HMDB00294</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
